Skip to main content

The antagonistic effects of temozolomide and trichostatin a combination on MGMT and DNA mismatch repair pathways in Glioblastoma


Glioblastoma is the most aggressive and fatal form of brain cancer. Despite new advancements in treatment, the desired outcomes have not been achieved. Temozolomide (TMZ) is the first-choice treatment for the last two decades and has improved survival rates. Emerging studies have shown that targeting epigenetics in glioblastoma can be beneficial when combined with clinically used treatments. Trichostatin A (TSA), a histone deacetylase inhibitor, has anti-cancer properties in various cancers. No data concerning the TMZ and TSA relationship was shown previously in glioblastoma therefore, we aimed to determine the likely therapeutic effect of the TMZ and TSA combination in glioblastoma. The T98G and U-373 MG, glioblastoma cell lines, were used in this study. TMZ and TSA cytotoxicity and combination index were performed by MTT assay. The expression of DNA repair genes (MGMT, MLH-1, PMS2, MSH2 and MSH6) was detected using RT-PCR. One-way analysis of variance (ANOVA) was used for statistical analysis. Combination index calculations revealed antagonistic effects of TMZ and TSA in terms of cytotoxicity. Antagonistic effects were more apparent in the T98G cell line, which is expressing MGMT relatively higher. MGMT and DNA Mismatch Repair (MMR) genes were upregulated in the T98G cell line, whereas downregulated in the U373-MG cell lines under TMZ and TSA combination treatment. It is concluded that MGMT might be playing a more active part than MMR genes in TMZ resistance to TMZ and TSA antagonism. This is the first study elucidating the TMZ and TSA relationship in cancer cell lines.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Data Availability

All data pertaining this study are included in the manuscript.


  1. Ostrom QT, et al. CBTRUS Statistical Report: primary brain and other Central Nervous System Tumors diagnosed in the United States in 2015–2019. Neuro Oncol. 2022;24(5):v1–v.

    Article  CAS  PubMed  Google Scholar 

  2. Tykocki T, Eltayeb M. Ten-year survival in glioblastoma. A systematic review. J Clin Neurosci. 2018;54:7–13.

    Article  PubMed  Google Scholar 

  3. Louis DN, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Silvani A. New perspectives: glioma in adult patients. Tumori J. p. Mar. 2023;030089162311597.

  5. Ståhl P, Henoch I, Smits A, Rydenhag B, Ozanne A. Quality of life in patients with glioblastoma and their relatives. Acta Neurol Scand. 2022;146(1):82–91.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Shi J, Dong B, Zhou P, Guan W, Peng Y. Functional network analysis of gene-phenotype connectivity associated with temozolomide. Oncotarget. 2017;8(50):87554–67.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Liu EK, Sulman EP, Wen PY, Kurz SC. Novel therapies for Glioblastoma. Curr Neurol Neurosci Rep. 2020;20(7).

  8. Lee P, et al. Mechanisms and clinical significance of histone deacetylase inhibitors: epigenetic glioblastoma therapy. Anticancer Res. 2015;35(2):615–25.

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Kunadis E, Lakiotaki E, Korkolopoulou P, Piperi C. Targeting post-translational histone modifying enzymes in glioblastoma. Pharmacol Ther. 2021;220:107721.

    Article  CAS  PubMed  Google Scholar 

  10. Zhang Y, Carr T, Dimtchev A, Zaer N, Dritschilo A, Jung M. Attenuated DNA damage repair by trichostatin a through BRCA1 suppression. Radiat Res. 2007;168(1):115–24.

    Article  CAS  PubMed  Google Scholar 

  11. Perla A, et al. Histone deacetylase inhibitors in Pediatric Brain Cancers: Biological Activities and therapeutic potential. Front Cell Dev Biol. 2020;8:1–14.

    Article  Google Scholar 

  12. Taspinar Çakir, Güven, Denizler K, Rüstemoğlu. “The Effect of Trichostatin A on Radiosensitivity in Glioblastoma,” Proceedings, vol. 40, no. 1, p. 22, 2019,

  13. Savran B, Yerlikaya A, Erdoğan E, Genç O. “Anticancer Agent Ukrain and Bortezomib Combination is Synergistic in 4T1 Breast Cancer Cells,” Anticancer. Agents Med. Chem, vol. 14, no. 3, pp. 466–472, Feb. 2014,

  14. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58(3):621–81.

    Article  CAS  PubMed  Google Scholar 

  15. Lan F, Yang Y, Han J, Wu Q, Yu H, Yue X. Sulforaphane reverses chemo-resistance to temozolomide in glioblastoma cells by NF-κB-dependent pathway downregulating MGMT expression. Int J Oncol. 2016;48(2):559–68.

    Article  CAS  PubMed  Google Scholar 

  16. Staberg M, Michaelsen SR, Rasmussen RD, Villingshøj M, Poulsen HS, Hamerlik P. Inhibition of histone deacetylases sensitizes glioblastoma cells to lomustine. Cell Oncol. 2017;40(1):21–32.

    Article  CAS  Google Scholar 

  17. Kato Y, et al. Contributing factors of temozolomide resistance in MCF-7 tumor xenograft models. Cancer Biol Ther. 2007;6(6):891–7.

    Article  CAS  PubMed  Google Scholar 

  18. Kitange GJ, et al. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. Neuro Oncol. 2009;11(3):281–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Perazzoli G, et al. Temozolomide resistance in glioblastoma cell lines: implication of MGMT, MMR, P-glycoprotein and CD133 expression. PLoS ONE. 2015;10(10):1–23.

    Article  CAS  Google Scholar 

  20. Meng CF, Zhu XJ, Peng G, Dai DQ. Role of histone modifications and DNA methylation in the regulation of O6-methylguanine-DNA methyltransferase gene expression in human stomach cancer cells. Cancer Invest. 2010;28(4):331–9.

    Article  CAS  PubMed  Google Scholar 

  21. Danam RP, Howell SR, Brent TP, Harris LC. Epigenetic regulation of O6-methylguanine-DNA methyltransferase gene expression by histone acetylation and methyl-CpG binding proteins. Mol Cancer Ther. 2005;4(1):61–9.

    Article  CAS  PubMed  Google Scholar 

  22. Bhakat KK, Mitra S. Regulation of the human O6-methylguanine-DNA methyltransferase gene by transcriptional coactivators cAMP response element-binding protein-binding protein and p300. J Biol Chem. 2000;275(44):34197–204.

    Article  CAS  PubMed  Google Scholar 

  23. Shinsato Y, et al. Reduction of MLH1 and PMS2 confers temozolomide resistance and is associated with recurrence of glioblastoma. Oncotarget. 2013;4(12):2261–70.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Meng CF, Su B, Li W. DNA demethylation is superior to histone acetylation for reactivating cancer-associated genes in ovarian cancer cells. Mol Med Rep. 2011;4(6):1273–8.

    Article  CAS  PubMed  Google Scholar 

  25. Imesch P, Dedes KJ, Furlato M, Fink D, Fedier A. MLH1 protects from resistance acquisition by the histone deacetylase inhibitor trichostatin A in colon tumor cells. Int J Oncol. 2009;35(3):631–40.

    Article  CAS  PubMed  Google Scholar 

  26. Kondo Y, Shen L, Issa J-PJ. Critical role of histone methylation in tumor suppressor gene silencing in Colorectal Cancer. Mol Cell Biol. 2003;23(1):206–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. McFaline-Figueroa JL, et al. Minor changes in expression of the mismatch repair protein MSH2 exert a major impact on glioblastoma response to temozolomide. Cancer Res. 2015;75:3127–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Castro GN, et al. Effects of temozolomide (TMZ) on the expression and interaction of heat shock proteins (HSPs) and DNA repair proteins in human malignant glioma cells. Cell Stress Chaperones. 2015;20(2):253–65.

    Article  CAS  PubMed  Google Scholar 

  29. Ponnusamy L, Mahalingaiah PKS, Chang YW, Singh KP. “Reversal of epigenetic aberrations associated with the acquisition of doxorubicin resistance restores drug sensitivity in breast cancer cells,” Eur. J. Pharm. Sci, vol. 123, no. June, pp. 56–69, 2018,

Download references


This study was funded by The Scientific and Technological Research Council of Turkey (Grant No: 1919B011802106) and the Van Yuzuncu Yıl University Scientific Research Council. Author M.G received the grants.

Author information

Authors and Affiliations



MG, JCS and MT conceived and designed research. MG and FDE conducted experiments. JCS contributed new reagents or analytical tools. MG, FT and MT analyzed data. MG and MT wrote the manuscript. All authors read and approved the manuscript.

Corresponding author

Correspondence to Mehmet Taşpınar.

Ethics declarations

Ethics approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Competing interests

The authors have no relevant financial or non-financial interests to disclose.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Güven, M., Taşpınar, F., Denizler-Ebiri, F.N. et al. The antagonistic effects of temozolomide and trichostatin a combination on MGMT and DNA mismatch repair pathways in Glioblastoma. Med Oncol 40, 223 (2023).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: